* The data is last updated on 10th February, 2023 from GISAID, based on 2379 variants from (14.9 million sequences) and 34 primer sets.
Browse
Prediction results retrieved after performance evaluation of WHO approved 34 primers to estimate their binding affinities for 2379 SARS-CoV-2 variants.

Lineage
(WHO label)
  
Target Gene
  
Primer Name
  
Primer Sequence
  
Primer Length
  
Primer GC Content (%)
  
Start Position
  
End Position
  
Primer Direction
  
ΔG (cal)
  
Primer first used
  
AY.122 (Delta)NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-20177US
BA.1 (Omicron)NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-23231.2US
BA.1.13.1NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-23231.2US
BF.26NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-23231.2US
CL.1NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-23231.2US
AY.100 (Delta)NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-23231.2US
BQ.1.1.18NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-23231.2US
BQ.1.1.10NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-23231.2US
BA.4.1NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-23231.2US
BA.1.1.13NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-23231.2US
AY.127 (Delta)NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-23231.2US
BA.2.32NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-23231.2US
BA.1.17.2NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-23231.2US
BA.1.18NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-23231.2US
B.1.429 (Epsilon)NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R1130.05US
BA.1.20NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-23231.2US
AY.44 (Delta)NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-2221.36US
BF.7NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-23231.2US
BA.5.5NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-23231.2US
BA.1.15NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-23231.2US
AY.98 (Delta)NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-23231.2US
AY.43 (Delta)NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-23231.2US
B.1.525 (Eta)NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-19265.8US
BA.2.3NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-23231.2US
B.1.1.70NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-23231.2US
BA.2.12.1NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-23231.2US
AY.5 (Delta)NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-23231.2US
R.1NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-23231.2US
BF.8NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-23231.2US
AY.103 (Delta)NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-2221.36US
B.1.177.7NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-23231.2US
AY.29 (Delta)NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-23231.2US
B.1.1.7 (Alpha)NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-23231.2US
B.1NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-2221.36US
BA.1.1.1NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-23231.2US
BA.1.1.2NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-23231.2US
BA.2 (Omicron)NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-23231.2US
AY.4.2 (Delta)NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-23231.2US
BA.5.1.17NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-23231.2US
BA.1.1 (Omicron)NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-23231.2US
BA.2.9NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-2221.36US
AY.4 (Delta)NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-23231.2US
BF.10NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-23231.2US
B.1.160NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-23231.2US
BQ.1.1NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-23231.2US
B.1.177NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-23231.2US
AY.111 (Delta)NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-23231.2US
BF.14NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-23231.2US
B.1.617.2 (Delta)NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-23231.2US
BA.5.6NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-23231.2US
Lineage
(WHO label)
  
Target Gene
  
Primer Name
  
Primer Sequence
  
Primer Length
  
Primer GC Content (%)
  
Start Position
  
End Position
  
Primer Direction
  
ΔG (cal)
  
Primer first used